Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Neurology|November 8, 2013
Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutationsGerald Pfeffer, Ailbhe Burke, Patrick Yu-Wai-Man, et al.Journal of Clinical Immunology|September 19, 2009
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosisSara A J Thompson, Joanne L Jones, Amanda L Cox, et al.Neurology|August 9, 2013
Immune competence after alemtuzumab treatment of multiple sclerosisClaire L McCarthy, Orla Tuohy, D Alastair S Compston, et al.Journal of Neurology|March 25, 2009
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's diseaseCaroline H Williams-Gray, An Goris, Misuzu Saiki, et al.The New England Journal of Medicine|October 24, 2008
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, Alasdair J Coles, D Alastair S Compston, et al.Plos One|February 24, 2012
Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferationMarija Sajic, David P J Hunt, Woojin Lee, et al.European Journal of Immunology|October 19, 2005
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosisAmanda L Cox, Sara A J Thompson, Joanne L Jones, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 14, 2010
Association of the human leucocyte antigen region with susceptibility to Parkinson's diseaseMisuzu Saiki, Amie Baker, Caroline H Williams-Gray, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 8, 2011
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosisGrant A Hill-Cawthorne, Tom Button, Orla Tuohy, et al.Neurology|October 14, 2016
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A Cohen, Alasdair J Coles, et al.Pageof 3